DENTSPLY SIRONA Inc. (XRAY) Stock Analysis and Metrics

Dentsply Sirona

NASDAQ: XRAY

$12.94 ▲ +0.22 (+1.69%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap2.59 Bn

P/E-4.13

P/S0.70

Div. Yield0.05

ROIC (Qtr)0.00

Total Debt (Qtr)2.24 Bn

Revenue Growth (1y) (Qtr)0.11

Add ratio to table…

About

DENTSPLY SIRONA Inc. is the world's largest diversified manufacturer of professional dental products and technologies, with a 139 year history of innovation and service to the dental industry. The company develops manufactures and markets comprehensive solutions that include technologically advanced dental equipment supported by cloud enabled software solutions as well as dental products and healthcare consumable products in urology and enterology under a strong portfolio of world class brands. Its mission is to transform oral health and continence care through innovative products solutions and services delivered by an engaged workforce.

The company generates revenue through the design manufacture and sale of dental technology and equipment products dental implants clear aligners and dental consumable products. It also sells healthcare consumable products for urological and enterological applications. Revenue is derived from sales to dental professionals dental laboratories hospitals and patients as well as through third party distributors. In addition the company offers cloud based services such as the DS Core platform that supports digital workflows and data management for dental practices.

The company operates through the following segments:.

• Connected Technology Solutions: This segment includes the design manufacture and sales of the company's dental technology and equipment products such as imaging equipment motorized dental handpieces treatment centers and CAD/CAM systems including intraoral scanners 3D printers mills and the CEREC chairside solution that enables same day restorations.

• Essential Dental Solutions: This segment includes the development manufacture and sales of value added endodontic restorative and preventive consumable products and small equipment used by dental professionals for patient treatment including motorized endodontic handpieces files sealers curing light systems dental ceramics composites ultrasonic scalers prophylaxis paste and impression materials.

• Orthodontic and Implant Solutions: This segment includes the design manufacture and sales of digital implant systems innovative dental implant products digital dentures and orthodontic solutions such as the SureSmile clear aligner system and related appliances as well as prosthetic components like crowns bridges and bone regenerative materials.

• Wellspect Healthcare: This segment includes the design manufacture and sales of innovative continence care solutions for urinary and bowel management including catheters for urinary retention irrigation systems for chronic constipation and associated accessories that improve patient comfort and clinical effectiveness.

DENTSPLY SIRONA Inc. holds a leading position in the global dental industry as the largest diversified manufacturer of professional dental products. The company faces competition from numerous firms that specialize in individual product categories but no single competitor matches the breadth of its portfolio. Its competitive advantages stem from well known brand names a comprehensive product line a reputation for high quality and innovation strong research and development capabilities a worldwide sales force an extensive distribution network and strong endorsement by dental and medical professionals. Additionally the company leverages its integrated digital ecosystem to offer seamless workflow solutions that enhance practice efficiency and patient outcomes.

The company serves a broad customer base that includes dental professionals dental laboratories hospitals and patients. Its products are distributed primarily through third party distributors with notable customers such as Henry Schein Inc. and Patterson Companies Inc. accounting for a significant portion of sales. In addition the company sells directly to dental clinics and institutions in select markets and provides its continence care products to medical distributors and end users.

Investment Thesis

▲ Bull case

Dentsply Sirona's strategic focus on AI-enabled diagnostic innovation like SmartView Detect, which provides 46% higher detection sensitivity in clinical evaluation, represents a significant underappreciated catalyst that could drive premium pricing and market share gains in the high-growth connected dentistry space. The integration of this technology into the DS Core platform creates a recurring revenue opportunity through software subscriptions and data services, which management did not emphasize during the call but is critical for long-term margin expansion. This innovation aligns with the company's Return to Growth plan by shifting focus from volume-dependent hardware sales to higher-margin digital solutions, potentially offsetting near-term gross margin pressures from tariffs and mix shifts. The early adoption signals from U.S. distributor partners like Benco installing CEREC systems under new agreements indicate that the commercial restructuring is beginning to yield traction faster than management acknowledged, suggesting the benefits of expanded distribution networks could materialize in Q3 rather than being delayed until 2027 as implied in the Q&A. Furthermore, the elimination of the dividend increases capital flexibility for accelerated debt reduction and potential share repurchases, which could support EPS growth even if revenue recovery lags, particularly given the company's current net debt to EBITDA ratio of 3.3x and $79 million in debt retired during Q1.
The company's restructuring program targeting $120 million in annual savings is progressing ahead of expectations, with OpEx already down $20 million on a constant currency basis in Q1, and these savings are being reinvested into R&D and commercial capabilities rather than being hoarded—a detail understated in the prepared remarks but highlighted in Daniel Scavilla's closing comments. This creates a virtuous cycle where cost discipline fuels innovation investment, which in turn drives future growth, contradicting the market's perception that the Return to Growth plan is solely a cost-cutting exercise. The strong performance of Wellspect Healthcare, growing 3.4% in constant currency with 4% EMEA growth led by new products like SureT, demonstrates successful diversification beyond core dental segments, providing a stable cash flow buffer that management did not leverage as a bullish point despite its consistency and margin resilience. Additionally, the geographic shift in reporting to Americas, EMEA, and APAC reveals hidden strength in APAC, where EDS showed double-digit growth and SureSmile posted 11% EMEA growth, indicating that regional execution improvements are already taking hold and could scale globally as the U.S. commercial restructuring takes effect in the second half of 2026.
Despite near-term headwinds from tariffs and destocking, the underlying dental market remains structurally stable as noted by management, and the company's broad portfolio positioning as a 'one-stop shop' for DSOs creates a durable competitive advantage that is underappreciated in current valuations. The ongoing conversations with multiple DSOs about active plans for the second half of 2026 and into 2027, combined with the leverage from bundled offerings, position XRAY to capture higher wallet share from consolidating practices—a trend that will accelerate as DSOs continue to grow globally. Furthermore, the FDA clearance of the dental-dedicated MRI, while not a near-term revenue driver, represents a strategic entry into soft tissue diagnostics that could open entirely new markets in veterinary and medical imaging, a long-term optionality not reflected in current guidance but mentioned by Scavilla as a potential source of future innovation. The company's commitment to maintaining investment-grade credit metrics while reducing debt, coupled with improving operating cash flow ($40 million vs $7 million prior year), provides a strong financial foundation to weather near-term volatility while executing its multi-year turnaround, a resilience factor the market is overlooking due to fixation on Q1's constant currency decline.

Dentsply Sirona's strategic focus on AI-enabled diagnostic innovation like SmartView Detect, which provides 46% higher detection sensitivity in clinical evaluation, represents a significant underappreciated catalyst that could drive premium pricing and market share gains in the high-growth connected dentistry space. The integration of this technology into the DS Core platform creates a recurring revenue opportunity through software subscriptions and data services, which management did not emphasize during the call but is critical for long-term margin expansion. This innovation aligns with the company's Return to Growth plan by shifting focus from volume-dependent hardware sales to higher-margin digital solutions, potentially offsetting near-term gross margin pressures from tariffs and mix shifts. The early adoption signals from U.S. distributor partners like Benco installing CEREC systems under new agreements indicate that the commercial restructuring is beginning to yield traction faster than management acknowledged, suggesting the benefits of expanded distribution networks could materialize in Q3 rather than being delayed until 2027 as implied in the Q&A. Furthermore, the elimination of the dividend increases capital flexibility for accelerated debt reduction and potential share repurchases, which could support EPS growth even if revenue recovery lags, particularly given the company's current net debt to EBITDA ratio of 3.3x and $79 million in debt retired during Q1.
The company's restructuring program targeting $120 million in annual savings is progressing ahead of expectations, with OpEx already down $20 million on a constant currency basis in Q1, and these savings are being reinvested into R&D and commercial capabilities rather than being hoarded—a detail understated in the prepared remarks but highlighted in Daniel Scavilla's closing comments. This creates a virtuous cycle where cost discipline fuels innovation investment, which in turn drives future growth, contradicting the market's perception that the Return to Growth plan is solely a cost-cutting exercise. The strong performance of Wellspect Healthcare, growing 3.4% in constant currency with 4% EMEA growth led by new products like SureT, demonstrates successful diversification beyond core dental segments, providing a stable cash flow buffer that management did not leverage as a bullish point despite its consistency and margin resilience. Additionally, the geographic shift in reporting to Americas, EMEA, and APAC reveals hidden strength in APAC, where EDS showed double-digit growth and SureSmile posted 11% EMEA growth, indicating that regional execution improvements are already taking hold and could scale globally as the U.S. commercial restructuring takes effect in the second half of 2026.
Despite near-term headwinds from tariffs and destocking, the underlying dental market remains structurally stable as noted by management, and the company's broad portfolio positioning as a 'one-stop shop' for DSOs creates a durable competitive advantage that is underappreciated in current valuations. The ongoing conversations with multiple DSOs about active plans for the second half of 2026 and into 2027, combined with the leverage from bundled offerings, position XRAY to capture higher wallet share from consolidating practices—a trend that will accelerate as DSOs continue to grow globally. Furthermore, the FDA clearance of the dental-dedicated MRI, while not a near-term revenue driver, represents a strategic entry into soft tissue diagnostics that could open entirely new markets in veterinary and medical imaging, a long-term optionality not reflected in current guidance but mentioned by Scavilla as a potential source of future innovation. The company's commitment to maintaining investment-grade credit metrics while reducing debt, coupled with improving operating cash flow ($40 million vs $7 million prior year), provides a strong financial foundation to weather near-term volatility while executing its multi-year turnaround, a resilience factor the market is overlooking due to fixation on Q1's constant currency decline.

▼ Bear case

Dentsply Sirona faces persistent and underappreciated gross margin pressure that extends beyond temporary tariff impacts, with Michael Pomeroy explicitly citing a 560 basis point gross profit decline driven by lower volumes, adverse product mix, and tariffs—factors that are unlikely to reverse quickly given the structural shift toward private label consumables and the company's admission that it does not intend to pursue significant price increases. The EDS 2025 inventory adjustment continues to weigh on margins, and the destocking trend in Europe, particularly in EDS where sales declined 7.2% due to Americas and EMEA weakness, signals deeper channel inventory issues that management characterized as a 'timing issue' but which could persist through 2026 given the PE-driven behavior of certain dealers. This margin erosion is compounded by the OIS segment's 13.5% constant currency decline (7.6% ex-Byte), reflecting ongoing implant volume weakness across all regions that Daniel Scavilla described as 'not happy with our performance to date,' with remedial actions still in early phases and no clear timeline for recovery beyond vague references to 2027–2028 improvements.
The Return to Growth plan's benefits are significantly delayed, with management explicitly stating that cost savings from restructuring will 'come through more in the fourth quarter than you would in the first half of the year' and that 'more of the improvements will be seen as we get into 2027 and certainly into 2028,' indicating that investors should not expect meaningful EPS accretion from cost cuts until well into 2027. This extended timeline contradicts the maintained full-year 2026 guidance of $1.40–$1.50 adjusted EPS, which appears increasingly optimistic given the 430 basis point EBITDA margin contraction in Q1 and the lack of tangible top-line growth drivers beyond Wellspect Healthcare's modest 3.4% constant currency increase. The elimination of the dividend, while framed as increasing capital flexibility, removes a key shareholder return mechanism and signals management's lack of confidence in near-term free cash flow generation, especially with operating cash flow still heavily dependent on working capital improvements ($40 million vs $7 million) rather than sustainable earnings growth. Furthermore, the company's net debt to EBITDA ratio of 3.3x remains elevated for a company undergoing turnaround, and the prioritization of debt reduction over growth investments limits the ability to reinvest savings into innovation at the pace needed to counteract competitive pressures.
Competitive threats are intensifying in core segments, particularly in iOS where new entrants are offering low-cost scanners and digital equipment, forcing Dentsply Sirona into a bundling strategy that may dilute margins and fail to counteract the pull-through advantages of simpler, cheaper alternatives—a dynamic Daniel Scavilla acknowledged but did not quantify in terms of market share loss or pricing pressure. The private label trend in consumables is described as having 'runway' with no indication of plateauing, yet the company admits it has no significant price increase plans for 2026, leaving it vulnerable to margin compression as it competes on non-price factors alone. Additionally, the lack of disclosure around new product contributions, with Scavilla stating they 'do not disclose that level of detail publicly' and agreeing that contributions will 'really start to step up maybe in 2027 and 2028,' suggests that innovation investments are not yielding near-term returns, increasing the risk that R&D spending becomes a drag on profitability without corresponding revenue acceleration. The ongoing investigation by Halper Sadeh LLC into potential fiduciary breaches by officers and directors introduces unquantified governance risk that could distract management, trigger costly settlements, or lead to adverse regulatory outcomes, a liability not reflected in current financials but which could materially impact shareholder value if substantiated.

Dentsply Sirona faces persistent and underappreciated gross margin pressure that extends beyond temporary tariff impacts, with Michael Pomeroy explicitly citing a 560 basis point gross profit decline driven by lower volumes, adverse product mix, and tariffs—factors that are unlikely to reverse quickly given the structural shift toward private label consumables and the company's admission that it does not intend to pursue significant price increases. The EDS 2025 inventory adjustment continues to weigh on margins, and the destocking trend in Europe, particularly in EDS where sales declined 7.2% due to Americas and EMEA weakness, signals deeper channel inventory issues that management characterized as a 'timing issue' but which could persist through 2026 given the PE-driven behavior of certain dealers. This margin erosion is compounded by the OIS segment's 13.5% constant currency decline (7.6% ex-Byte), reflecting ongoing implant volume weakness across all regions that Daniel Scavilla described as 'not happy with our performance to date,' with remedial actions still in early phases and no clear timeline for recovery beyond vague references to 2027–2028 improvements.
The Return to Growth plan's benefits are significantly delayed, with management explicitly stating that cost savings from restructuring will 'come through more in the fourth quarter than you would in the first half of the year' and that 'more of the improvements will be seen as we get into 2027 and certainly into 2028,' indicating that investors should not expect meaningful EPS accretion from cost cuts until well into 2027. This extended timeline contradicts the maintained full-year 2026 guidance of $1.40–$1.50 adjusted EPS, which appears increasingly optimistic given the 430 basis point EBITDA margin contraction in Q1 and the lack of tangible top-line growth drivers beyond Wellspect Healthcare's modest 3.4% constant currency increase. The elimination of the dividend, while framed as increasing capital flexibility, removes a key shareholder return mechanism and signals management's lack of confidence in near-term free cash flow generation, especially with operating cash flow still heavily dependent on working capital improvements ($40 million vs $7 million) rather than sustainable earnings growth. Furthermore, the company's net debt to EBITDA ratio of 3.3x remains elevated for a company undergoing turnaround, and the prioritization of debt reduction over growth investments limits the ability to reinvest savings into innovation at the pace needed to counteract competitive pressures.
Competitive threats are intensifying in core segments, particularly in iOS where new entrants are offering low-cost scanners and digital equipment, forcing Dentsply Sirona into a bundling strategy that may dilute margins and fail to counteract the pull-through advantages of simpler, cheaper alternatives—a dynamic Daniel Scavilla acknowledged but did not quantify in terms of market share loss or pricing pressure. The private label trend in consumables is described as having 'runway' with no indication of plateauing, yet the company admits it has no significant price increase plans for 2026, leaving it vulnerable to margin compression as it competes on non-price factors alone. Additionally, the lack of disclosure around new product contributions, with Scavilla stating they 'do not disclose that level of detail publicly' and agreeing that contributions will 'really start to step up maybe in 2027 and 2028,' suggests that innovation investments are not yielding near-term returns, increasing the risk that R&D spending becomes a drag on profitability without corresponding revenue acceleration. The ongoing investigation by Halper Sadeh LLC into potential fiduciary breaches by officers and directors introduces unquantified governance risk that could distract management, trigger costly settlements, or lead to adverse regulatory outcomes, a liability not reflected in current financials but which could materially impact shareholder value if substantiated.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ALC	Alcon Inc	33,163,703.85 Bn	498,335.12	3.14 Mn	4.16 Bn
2	ISRG	Intuitive Surgical Inc	119.67 Bn	37.90	0.00 Mn	-
3	BDX	Becton Dickinson & Co	43.92 Bn	37.38	0.00 Mn	17.28 Bn
4	MDLN	Medline Inc.	31.71 Bn	56.52	0.00 Mn	12.57 Bn
5	RMD	Resmed Inc	28.46 Bn	18.73	0.00 Mn	0.66 Bn
6	WST	West Pharmaceutical Services Inc	23.80 Bn	45.05	0.00 Mn	0.20 Bn
7	COO	Cooper Companies, Inc.	13.77 Bn	58.38	0.00 Mn	2.46 Bn
8	SOLV	Solventum Corp	13.63 Bn	9.51	0.00 Mn	5.08 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password